UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 103 filers reported holding UROGEN PHARMA LTD in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $136,808 | +40.4% | 9,765 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $97,466 | +16.0% | 9,417 | -2.8% | 0.00% | – |
| Q1 2022 | $84,000 | -15.2% | 9,685 | -6.6% | 0.00% | – |
| Q4 2021 | $99,000 | -45.0% | 10,367 | -2.9% | 0.00% | -100.0% |
| Q3 2021 | $180,000 | +7.8% | 10,676 | -2.3% | 0.00% | 0.0% |
| Q2 2021 | $167,000 | -24.1% | 10,930 | -3.2% | 0.00% | 0.0% |
| Q1 2021 | $220,000 | +8.4% | 11,296 | +0.3% | 0.00% | 0.0% |
| Q4 2020 | $203,000 | -9.4% | 11,267 | -2.8% | 0.00% | 0.0% |
| Q3 2020 | $224,000 | -27.7% | 11,591 | -2.2% | 0.00% | 0.0% |
| Q2 2020 | $310,000 | +56.6% | 11,853 | +6.9% | 0.00% | 0.0% |
| Q1 2020 | $198,000 | -49.5% | 11,091 | -5.5% | 0.00% | -50.0% |
| Q4 2019 | $392,000 | +39.0% | 11,733 | -0.8% | 0.00% | +100.0% |
| Q3 2019 | $282,000 | -34.1% | 11,831 | -0.7% | 0.00% | -50.0% |
| Q2 2019 | $428,000 | – | 11,913 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,620,545 | $36,713,835 | 6.69% |
| Wildcat Capital Management, LLC | 495,606 | $6,943,440 | 2.79% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 508,883 | $7,129,451 | 2.16% |
| Opaleye Management Inc. | 320,000 | $4,483,200 | 1.46% |
| AlphaCentric Advisors LLC | 165,000 | $2,311,650 | 1.31% |
| Soleus Capital Management, L.P. | 372,000 | $5,211,720 | 0.48% |
| EAM Investors, LLC | 170,523 | $2,389,027 | 0.46% |
| RA Capital Management | 1,483,697 | $20,786,595 | 0.41% |
| Parkman Healthcare Partners LLC | 145,311 | $2,035,807 | 0.37% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 | $32,265,464 | 0.29% |